2379776-40-4
2379776-40-4
Chemical Structure
Plozasiran
Synonym(s): ARO-APOC3
- CAS No.: 2379776-40-4
- Formula:N/A
- Molecular Weight:15618.77
SMILES: [Plozasiran]
Biological Activity: Plozasiran (ARO-APOC3) is a siRNA targeting APOC3. Plozasiran mediates RNA interference-mediated degradation and silencing of APOC3 mRNA, reducing APOC3 synthesis and expression, apoC3 protein expression, and plasma ApoC3 concentrations. Plozasiran reduces fasting and non-fasting plasma triglyceride concentrations in diet-induced hypertriglyceridemia. Plozasiran can be used in research on hypertriglyceridemia, mixed hyperlipidemia, and mixed dyslipidemia[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Plozasiran | 99.00% | Plozasiran (ARO-APOC3) is a siRNA targeting APOC3. Plozasiran mediates RNA interference-mediated degradation and silencing of APOC3 mRNA, reducing APOC3 synthesis and expression, apoC3 protein expression, and plasma ApoC3 concentrations. Plozasiran reduces fasting and non-fasting plasma triglyceride concentrations in diet-induced hypertriglyceridemia. Plozasiran can be used in research on hypertriglyceridemia, mixed hyperlipidemia, and mixed dyslipidemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ballantyne CM, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. The New England journal of medicine. 2024 Sep 12;391(10):899-912.
- [2]. Prakash TP, et al. Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. Nucleic acids research. 2025 Oct 28;53(20):gkaf1063.
- [3]. Ballantyne C, et al. Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results. Atherosclerosis. 2024 Aug 1;395.
- [4]. Butler AA, et al. Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. Journal of lipid research. 2019 Apr;60(4):805-818.
- [5]. Vasas S, et al. † Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of Clinical Lipidology. 2024 Jul 1;18(4):e560.
